Should COVID-19 be considered cardiovascular disease risk equivalent?

Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad

Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad.

Kow CS; School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom. Electronic address: chiasiang_93@hotmail.com.
Ramachandram DS; School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
Hasan SS; School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom; School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

Int J Cardiol ; 377: 123, 2023 04 15.

Article in English | MEDLINE | ID: covidwho-2210435

Subject(s)

COVID-19; Cardiovascular Diseases; Humans; Cardiovascular Diseases/diagnosis; Cardiovascular Diseases/epidemiology; SARS-CoV-2; Risk Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Int J Cardiol Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google